Stifel Maintains Buy on HilleVax, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey has maintained a Buy rating on HilleVax (NASDAQ:HLVX) but has reduced the price target from $35 to $30.
November 10, 2023 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst Stephen Willey maintains a Buy rating on HilleVax but lowers the price target from $35 to $30.
While the reduction in price target could suggest a more conservative valuation or perceived near-term headwinds, the maintenance of a Buy rating indicates a continued positive outlook on the company's fundamentals. The impact on the stock price is likely to be mixed in the short term, as the market weighs the lower price target against the reaffirmed confidence from the analyst.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100